While Mounjaro is only FDA-approved to treat type 2 diabetes at this time, it may gain approval for weight loss in the near future
Key Points Native human GLP-1 normalizes hyperglycaemia in patients with type 2 diabetes mellitus, but the short in vivo half-life of this hormone limits its therapeutic application A number of synthetic GLP-1 receptor agonists, with half-lives between 23 h and several days, have been developed for the long-term treatment of type 2 diabetes mellitus Short-acting GLP-1 receptor agonists (such as exenatide and lixisenatide) predominantly lower postprandial glucose levels and insulin concentrations via retardation of gastric emptying Long-acting GLP-1 receptor agonists (such as albiglutide, dulaglutide, exenatide long-acting release and liraglutide) predominantly lower blood glucose levels through stimulation of insulin secretion and reduction of glucagon levels Adverse effects of GLP-1 receptor agonists include nausea, vomiting and diarrhoea, injection-site reactions, antibody formation and increased heart rate This is a preview of subscription content, access via your institution Access options Subscribe to this journal Receive 12 print issues and online access $189.00 per year only $15.75 per issue Buy this article Purchase on SpringerLink Instant access to the full article PDF
How we evaluated Pendulum probiotics We evaluated Pendulums probiotics based on four criteria that are likely to influence consumers purchasing decisions: Effectiveness: Can Pendulums capsules deliver well-researched probiotic species in clinically relevant numbers to the intestines and colon, where they can do their work
Insulin lowers your blood sugar by helping the cells in your body use the sugar for energy
Who taking a GLP-1 RA is not at increased risk of delayed gastric emptying when that is the very mechanism by which the drugs work
Proper injection technique includes maintaining 2.55 cm distance between consecutive injections and avoiding scars, moles, or areas with skin abnormalities
